Company / Operating Cash Flow
Allogene Therapeutics, Inc. Operating Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$149.2M
FY2025
5-year range
-$237.7M / -$110.8M
FY2021-FY2025
Trend
+37.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$149M.
Based on SEC 10-K filings.
-$149M in FY2025.
Improved from -$185M to -$149M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 37.2% year-over-year.
- Peak operating cash flow was recorded in FY2022.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$149.2M | +37.2% |
| FY2024 | -$237.7M | -28.6% |
| FY2023 | -$184.8M | -66.8% |
| FY2022 | -$110.8M | +19.4% |
| FY2021 | -$137.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026